LonzaPeripheralBloodMononuclearCells(PBMCs)
GreaterThan50MillionViableCells perVial
Lonza PeripheralBloodMononuclearCells(PBMCs)areisolatedfromperipheralbloodbyapheresisanddensitygr
ADIentseparation.Theyare guaranteedtocontain≥50millionviablecellsperampoule.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.
ABIlitytoScreenDifferentDonors Samplerepresentationinyourexperimentmatters.Wemaintainan inventoryofdifferentdonorsinanefforttosatisfyyoursamplerepresentationrequirements.Youcanchoosealotbasedondonordemographiccharacteristics,andscreenmultiplelotstofindthelot(s)thatworkbestforyou. Inaddition,wecanrequestrepeatdonorsifyouneedadditionalcellsfromaparticulardonor.
RequestPBMCInventoryInformation
RichSourceofImmuneCells
Peripheralbloodmononuclearcells(PBMC)areamixedpopulationofsinglenucleuscells.Theycanbefurtherpurified toisolate individualcell typessuchas naturalkillercells,Tcells,andBcells.Inaddition,PMBCsarearichsourceofmonocytes,whichcanbedirectedtodifferentiateintoeithermacrophagesordendriticcellsthroughculturewithvariouscytokines.
SupportedbyanOptimizedMediaSystem
LGM-3™LymphocyteGrowthMediumwasspecificallydesignedforsupportandmaintenanceoflymphocytesandisoptimizedforserum-freeculturing(additionalcytokinesmaybenecessarydependingonapplication)Alternativemediacontainingserummayalsobeacceptable.PleasecontactScientificSupportforserumcontainingmediarecommendations.
LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.
龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach,公司经营范围包括:生物技术开发服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术推广服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术咨询、交流服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);生物技术转让服务(我国稀有和特有的珍贵优良品种,国家保护的原产于我国的野生动、植物资源开发除外);医学研究和试验发展(人体干细胞、基因诊断与治疗技术除外);药品研发(人体干细胞、基因诊断与治疗技术除外);货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易(涉及外资准入特别管理规定和许可审批的商品除外);生物药品制造;化学药品原料药制造;化学药品制剂制造等。